Skip to main content

Table 1 Number of patients with related adverse events by CTCAE grading

From: Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

Related adverse events

CTCAE grade

Any grade

MedDRA preferred term

1

2

3

Pyrexia

12

9

2

12

Chills

9

6

 

10

Fatigue

10

5

1

10

Injection site pain

8

3

 

9

Decreased appetite

8

1

 

8

Feeling cold

7

2

 

8

Hyperhidrosis

5

4

 

8

Nausea

6

  

6

Anaemia

3

4

1

5

Pain

3

3

 

5

Vomiting

5

2

 

5

Headache

3

3

 

4

Blood alkaline phosphatase increased

 

1

2

3

Injection site haematoma

3

  

3

Night sweats

2

2

 

3

Abdominal distension

2

1

 

2

Dyspnoea

1

1

1

2

Pneumonia

 

2

 

2

Somnolence

2

  

2

Upper respiratory tract infection

 

2

 

2

Aspartate aminotransferase increased

  

1

1

C-reactive protein increased

 

1

 

1

Dyspepsia

 

1

 

1

Hepatic pain

1

1

 

1

Hypoalbuminaemia

  

1

1

Hyponatraemia

  

1

1

Myalgia

1

1

 

1

Oedema peripheral

 

1

1

1

Oral herpes

 

1

 

1

Proteinuria

  

1

1

Abdominal pain upper, Arthralgia, Back pain, Cough, Dizziness, Dyspnoea exertional, Eczema, Haematoma, Hypovolaemia, Injection site haemorrhage, Iron deficiency, Libido decreased, Lymphadenopathy, Malaise, Muscle strain, Muscular weakness, Oedema, Peripheral coldness, Polyuria, Post procedural haemorrhage, Pruritus, Urticaria

1

  

1

  1. No grade 4–5 events were reported